Breaking news

J&J to buy Crucell for $2.3bn

- Last updated on GMT

Related tags: Vaccine, Biotechnology

Johnson & Johnson is in advanced talks to buy biotechnology firm Crucell to boost vaccine development and manufacturing capacity.

US healthcare major J&J, which bought an 18 percent stake in Crucell last year​, said the Dutch firm’s strength in the manufacture, discovery and commercialization of vaccines would create a strong platform for it in the market.

J&J expects to pay around €1.75bn ($2.3bn) in cash for Leiden, the Netherlands-headquartered Crucell, but did not disclose when the deal would be completed.

At this stage it is unclear what impact, if any, the acquisition will have on the numerous ​licensing agreements Crucell has with biomanufacturers that use the PER.C6 cell line technology it developed in partnership with DSM.

Related topics: Bio Developments

Related news

Show more

Follow us

Products

View more

Webinars